Outcomes of Ultimpro Testing Implementation for Patients With Unexplained Recurrent Implantation Failure: A...

Area of Science:

• Reproductive Immunology
• Assisted Reproductive Technology
• Genomics and Proteomics

Background:

• A subset of patients with unexplained recurrent implantation failure (uRIF) may experience endometrial immune dysregulation.
• The Ultimpro test analyzes endometrial immunophenotypes to detect and characterize immune dysregulation.
• Personalized adjustments to embryo transfer (ET) protocols can be proposed based on Ultimpro results.

Purpose of the Study:

• To evaluate the effectiveness of the Ultimpro endometrial immunophenotype test in patients with uRIF.
• To assess if Ultimpro-guided protocols improve pregnancy and live birth rates compared to standard care.
• To compare outcomes in patients with and without RIF undergoing Ultimpro testing.

Main Methods:

• A retrospective cohort study analyzed 121 patients over 2.5 years.
• Group 1 (93 patients) had uRIF and underwent Ultimpro testing; outcomes compared to a control group (94 uRIF patients).
• Group 2 (28 patients) without RIF were compared to Canadian average ongoing pregnancy rates (OPR).

Main Results:

• Group 1 (uRIF) showed a significantly higher pregnancy rate (49.5%) with Ultimpro compared to controls (33%, p=0.026).
• Patients with ≥5 failed blastocyst transfers particularly benefited (55.3% vs. 20.0%, p=0.0084).
• Group 2 (no RIF) did not show improved OPR per ET with Ultimpro recommendations compared to non-RIF averages.

Conclusions:

• Preliminary findings suggest Ultimpro recommendations improve successful outcomes in uRIF patients.
• The test did not show a benefit for patients without RIF.
• Further validation through a large-scale randomized controlled trial is warranted.